<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="888">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05149599</url>
  </required_header>
  <id_info>
    <org_study_id>2731020MSGE</org_study_id>
    <nct_id>NCT05149599</nct_id>
  </id_info>
  <brief_title>Saccharomyces Cerevisiae for Irritable Bowel Syndrome</brief_title>
  <acronym>IBS</acronym>
  <official_title>Efficacy and Safety of Saccharomyces Cerevisiae for Abdominal Pain and Discomfort in Irritable Bowel Syndrome (IBS) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ziauddin University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hilton Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ziauddin University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to see the response of saccharomyces cerevisiae for symptomatic&#xD;
      improvement of patients with IBS&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Actual">October 31, 2021</completion_date>
  <primary_completion_date type="Actual">October 31, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the response of saccharomyces cerevisiae for symptomatic improvement in patients with IBS through pain/ discomfort score</measure>
    <time_frame>One month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the response of saccharomyces cerevisiae for symptomatic improvement in patients with IBS through IBS quality of life questionnaire</measure>
    <time_frame>One month</time_frame>
    <description>IBS quality of life questionnaires at baseline and at 1 month</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Treated patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saccharomyces cerevisiae</intervention_name>
    <description>Saccharomyces cerevisiae, which is a pro-biotic, was given in capsule form, 500mg twice daily for 1 month</description>
    <arm_group_label>Treated patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients between 18 and 75 years of age,&#xD;
&#xD;
          -  Patients having confirmed IBS according to Rome IV criteria (newly and previously&#xD;
             non-responder to treatment),&#xD;
&#xD;
          -  Pain/ discomfort score strictly above 1 and strictly below 6 as determined on a pain/&#xD;
             discomfort scale using arbitrary grading from 0 to 7 in 7 days preceding the inclusion&#xD;
             visit,&#xD;
&#xD;
          -  Not hypersensitive to any of the ingredients of the drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with an organic intestinal disease (Crohn's disease, ulcerative colitis,&#xD;
             etc.),&#xD;
&#xD;
          -  Pregnant females&#xD;
&#xD;
          -  Treatments likely to influence IBS (anti-depressants, opioids, and narcotic&#xD;
             analgesics)&#xD;
&#xD;
          -  Patients with chronic alcoholism, vegetarian or vegan regimens&#xD;
&#xD;
          -  Eating disorders such as anorexia or bulimia&#xD;
&#xD;
          -  Documented food allergies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mehreen Siyal, MBBS, FCPS-1</last_name>
    <role>Principal Investigator</role>
    <affiliation>DR ZIAUDDIN HOSPITAL, CLIFTON CAMPUS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr. Ziauddin University Hospital Clifton</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <zip>75600</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 24, 2021</study_first_submitted>
  <study_first_submitted_qc>November 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2021</study_first_posted>
  <last_update_submitted>November 24, 2021</last_update_submitted>
  <last_update_submitted_qc>November 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ziauddin University</investigator_affiliation>
    <investigator_full_name>DR MREHREEN SIYAL</investigator_full_name>
    <investigator_title>Resident Gastroenterology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

